<SEC-DOCUMENT>0001193125-18-179489.txt : 20180531
<SEC-HEADER>0001193125-18-179489.hdr.sgml : 20180531
<ACCEPTANCE-DATETIME>20180531080033
ACCESSION NUMBER:		0001193125-18-179489
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180531
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180531
DATE AS OF CHANGE:		20180531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		18870040

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d598105d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;31, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;31, 2018, FibroGen, Inc. and its collaboration partner,
Astellas Pharma Inc., issued a press release in which they announced topline results from the double-blind Phase 3 study completed in Japan by Astellas Pharma Inc. for roxadustat in hemodialysis-dependent chronic kidney disease patients with anemia.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of such press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d598105dex991.htm">Press Release titled &#147;Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia&#148; dated May&nbsp;31,
 2018 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FIBROGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: May&nbsp;31, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Legal Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d598105dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g598105g0531061128430.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g598105g0531061214295.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Press Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Astellas and FibroGen Announce Topline Results </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>from Double-Blind Japan Phase 3 Study for </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Roxadustat in Hemodialysis Chronic Kidney Disease </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patients with Anemia </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TOKYO and San
Francisco, May 31, 2018</B> - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., &#147;Astellas&#148;) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, &#147;FibroGen&#148;) today announced that the fourth Japan Phase 3
study for roxadustat met its primary endpoint. This study evaluated the efficacy and safety of roxadustat compared to darbepoetin alfa (genetical recombination) (&#147;darbepoetin alfa&#148;) in hemodialysis-dependent chronic kidney disease (CKD)
patients with anemia and previously treated with recombinant human erythropoietin (rHuEPO) or darbepoetin alfa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are encouraged by these positive
data from our Phase 3 key study in Japan, and are pleased with our overall development progress to date in the region,&#148; said Salim Mujais, M.D., senior vice president and global therapeutic area head, Medical Specialties Development, Astellas.
&#147;We look forward to continuing to advance the development of roxadustat to hopefully provide the value of a new therapeutic option to patients suffering from CKD with anemia.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The positive topline results from this latest Japan Phase 3 study are consistent with previously reported results from roxadustat Phase 3 studies in
Japan and in China, and from our extensive Phase 2 program,&#148; said K. Peony Yu, M.D., Chief Medical Officer, FibroGen. &#147;We are pleased with the growing body of clinical evidence showing roxadustat to be well tolerated and efficacious in
treating anemia in CKD patients, including patients on hemodialysis and those on peritoneal dialysis in various regions worldwide.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the study,
average hemoglobin (Hb) levels were effectively maintained at 10.99&nbsp;g/dL at Weeks 18 to 24 in roxadustat-treated hemodialysis patients previously treated with erythropoiesis-stimulating agents (ESAs). The primary efficacy endpoint of change in
average Hb levels from baseline to Weeks 18 to 24 was <FONT STYLE="white-space:nowrap">-0.04</FONT> g/dL and <FONT STYLE="white-space:nowrap">-0.03</FONT> g/dL in the roxadustat-treated group and in the darbepoetin-treated group, respectively. The <FONT
STYLE="white-space:nowrap">non-inferiority</FONT> of roxadustat to darbepoetin alfa in change of average Hb from baseline was confirmed as the lower bound of the 95% confidence interval <FONT STYLE="white-space:nowrap">(-0.18,</FONT> 0.15) of the
treatment difference was greater than the <FONT STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap">non-inferiority</FONT> margin <FONT STYLE="white-space:nowrap">(-0.75</FONT> g/dL). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat was well tolerated in this study, and the safety profile of roxadustat was consistent with that observed in previous studies both in dialysis and <FONT
STYLE="white-space:nowrap">non-dialysis</FONT> patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further detailed data from this study are expected to be reported in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas is a sponsor of a total of six Phase 3 studies of roxadustat in Japan for anemia associated with CKD in
both dialysis and <FONT STYLE="white-space:nowrap">non-dialysis</FONT> patients. This study is the final Phase 3 study in Japan evaluating roxadustat for the treatment of anemia in CKD patients on dialysis. Astellas is planning the submission of the
new drug application in Japan for this indication later this year. The two Japan Phase 3 studies in <FONT STYLE="white-space:nowrap">non-dialysis</FONT> patients are ongoing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The multi-center, randomized,
darbepoetin alfa-controlled, double-blind Phase 3 study enrolled a total of 303 hemodialysis chronic kidney disease patients with anemia converted from rHuEPO or darbepoetin alfa. Subjects randomized to the roxadustat treatment arm received
roxadustat three times a week orally and darbepoetin alfa placebo. Subjects randomized to the darbepoetin alfa treatment arm received darbepoetin-alfa once a week intraveneously and roxadustat placebo. The primary efficacy endpoint is change of
average Hb levels from baseline during the evaluation period of Weeks 18 to 24. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Chronic Kidney Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CKD affects more than 200&nbsp;million people worldwide<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> and specifically in Japan, the prevalence of CKD
has increased significantly over time.<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> Although it can occur at any age, it becomes more common in aging populations, and the prevalence is increasing. Anemia is a common complication of CKD and
is associated with significant morbidity and mortality in dialysis and <FONT STYLE="white-space:nowrap">non-dialysis</FONT> populations. In addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide
healthcare issue that represents a large and growing unmet medical need. Currently, no curative treatment or ability to stop kidney deterioration in patients with CKD exists with the exception of kidney transplantation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roxadustat </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat is currently in Phase 3
development as a potential therapy for anemia associated with CKD in both patients on dialysis and not on dialysis. Roxadustat is an orally administered small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase activity. HIF is a
protein transcription factor that induces the natural physiological response to conditions of low oxygen, &#147;turning on&#148; erythropoiesis (the process by which red blood cells are produced). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in patients with CKD in territories
including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in patients with CKD in
the U.S., China, and other markets. Roxadustat is also in clinical development for anemia in MDS. For information about roxadustat studies that are currently recruiting patients, please visit clinicaltrials.gov at this link:
<U>https://clinicaltrials.gov/ct2/results?term=roxadustat&amp;Search=Search</U>. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ojo, A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. <I>Transactions of the American Clinical and Climatological Association</I>. 2014; 125: <FONT
STYLE="white-space:nowrap">229-246.</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, Tsuruya K, Iida M, Kiyohara Y. <I>Nephrol Dial
Transplan</I>t. 2010 Aug; <FONT STYLE="white-space:nowrap">25(8):2557-64.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Astellas </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and
reliable pharmaceutical products. For more information, please visit our website at <U>https://www.astellas.com/en</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#146;s Republic of China, is a leading
science-based biopharmaceutical company discovering and developing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in
hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#146;s most advanced product
candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), except in China, where a New Drug Application is currently under
review by the State Drug Administration, or SDA (formerly the China Food and Drug Administration, or CFDA). Roxadustat is also in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes
(MDS).&nbsp;Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase&nbsp;2 trial for Duchenne
muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit <U>www.fibrogen.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Astellas Cautionary Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this press release,
statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on
management&#146;s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed
in the forward-looking statements. Such factors include, but are not limited to: (i)&nbsp;changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii)&nbsp;currency exchange rate fluctuations,
(iii)&nbsp;delays in new product launches, (iv)&nbsp;the inability of Astellas to market existing and new products effectively, (v)&nbsp;the inability of Astellas to continue to effectively research and develop products accepted by customers in
highly competitive markets, and (vi)&nbsp;infringements of Astellas&#146; intellectual property rights by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about pharmaceutical
products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FibroGen Forward-looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release
contains forward-looking statements regarding FibroGen strategy, future plans, and prospects, including statements regarding the development of the company&#146;s product candidates pamrevlumab and roxadustat, the potential safety and efficacy
profile of our product candidates, and our clinical, regulatory, and commercial plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and
contentions and are not historical facts and typically are identified by use of terms such as &#147;may,&#148; &#147;will&#148;, &#147;should,&#148; &#147;on track,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148;
&#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ
materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical
trials, and other matters that are described in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
for the fiscal quarter ended March&nbsp;31, 2018, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contacts for inquiries or additional information:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEL: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+81-3-3244-3201</FONT></FONT> FAX: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">+81-3-5201-7473</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kbergman@fibrogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g598105g0531061128430.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g598105g0531061128430.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ .0# 2(  A$! Q$!_\0
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M-\,:C%%JD925'CE&PE6R.?I[XJU9H\FK0JT7:I%KU/0J***#(**** "BBB@
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M6D!IZ=J4&IV[30+(JJY0AUP0< _UHJ6WM8K4S&($>=(96_WB!G^5% $]%%%
M#9'6*-I'.%0%F/H!7#^'/"2WVHR^)=;BWW5S(98+>0<1*?N[AZ@8P.WUZ=T0
M",$9!HI-7.BEB9T82C#1RZ^7;YA7)>+[K?/!:)SM&YA[GI_GWKJY'$<;.>B@
MDUE66DJ;IM1NRLEQ(=R@?=3T^M,YROX=T3[%&+JX7]^X^53_  #_ !K?HHH
M*IZK>G3]+N+H %HU^4'U)P/U-7*@O;2.^LI;67(21<$CMZ&@#G/#EBFJP-J>
MHG[5,[E5$G*J..W2H/&T<$%K9QQQQQL7) 50.!BG6&EZWHTK6MK=VS1.V0)
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E7-C9BWGC,[(<!V/./2BNITWP]96%H(719W)W,[KU/M[44P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g598105g0531061214295.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g598105g0531061214295.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K *4# 2(  A$! Q$!_\0
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K2?4UIT47 S-2\/:7J]W;75_:B::V.86WL-IR#V//('6M.BBD 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
